DSGN Earnings & Financial Statements
Design Therapeutics, Inc.
$12.42
+$0.08(+0.65%)
37
Overall
60
Value
27
Tech
26
Quality
Market Cap
$772.26M
Volume
680.74K
52W Range
$5.28 - $17.25
Target Price
$20.86
DSGN earnings and financial statements: Design Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DSGN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M |
| EBITDA | -$69.17M | -$48.99M | -$66.33M | -$67.19M | -$35.46M |
| Net income | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M |
| EPS (diluted) | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $226.20M | $252.09M | $289.64M | $341.14M | $390.56M |
| Total liabilities | $13.70M | $10.00M | $11.96M | $13.83M | $8.43M |
| Shareholders’ equity | $212.50M | $242.10M | $277.69M | $327.31M | $382.13M |
| Cash and equivalents | $16.86M | $22.56M | $21.20M | $26.50M | $298.57M |
| Long-term debt | $645.0K | $1.53M | $2.33M | $3.05M | $3.14M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.36M | -$43.10M | -$58.56M | -$51.32M | -$29.38M |
| Capital expenditure | -$193.0K | -$340.0K | -$256.0K | -$918.0K | -$1.54M |
| Free cash flow | -$54.55M | -$43.45M | -$58.82M | -$52.23M | -$30.91M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DSGN | $12.42 | +0.6% | 680.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Design Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW